Patients with estrogen receptor–positive, #HER2 -negative advanced #BreastCancer experienced significantly longer progression-free survival when treated with an oral #CombinationTherapy that included #giredestrant, a next-generation selective #EstrogenReceptor degrader and complete antagonist.
sbee.link
Novel combination therapy improves progression-free survival in most common form of metastatic breast cancer – BioNews Central
Patients with estrogen receptor–positive, HER2-negative advanced breast cancer experienced significantly longer progression-free survival when treated with an oral combination therapy that included giredestrant, a next-generation selective estrogen r
